Report: Baxalta’s $2B plot to buy Ariad broke down over price

Damian Garde

Last week's buzz that Baxalta, angling to shake off some unwanted buyout attention from Shire, had set sights on Pharmaceuticals sent the latter company's shares soaring. But negotiations between the two have since fallen apart, according to Bloomberg.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS